|Mr. Chirag K. Patel||Co-Founder, Co-CEO, Pres & Director||22,04k||N/A||1967|
|Mr. Chintu Patel R.Ph., R.Ph||Co-Founder, Co-CEO & Director||29,85k||N/A||1972|
|Mr. Anastasios G. Konidaris||Exec. VP & CFO||856,85k||N/A||1967|
|Ms. Nikita Shah||Exec. VP and Chief HR Officer & Strategic Planning Officer||720,52k||N/A||1978|
|Mr. Joseph Todisco MBA||Exec. VP & Chief Commercial Officer of Specialty||790,12k||N/A||1976|
|Mr. Andrew S. Boyer||Exec. VP & Chief Commercial Officer of Generics||1,15M||N/A||1966|
|Mr. Stephen J. Manzano||Sr. VP, Gen. Counsel & Corp. Sec.||N/A||N/A||1965|
|Mr. Sanjiv Patel||Sr. VP of Operations||N/A||N/A||N/A|
|Dr. Nikunj Patel||Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd||N/A||N/A||N/A|
|Mr. Sanjay Kumar Jain||Pres of India Operations||N/A||N/A||N/A|
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Amneal Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2021, lautet 6. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 4, Kompensation: 4.